Drug Profile
Research programme: coronavirus neutralising antibodies - AbCellera/Eli Lilly and Company
Alternative Names: coronavirus (2019-nCoV) neutralising antibodies - AbCellera/Eli Lilly and Company; SARS-CoV-2-neutralizing antibodies - AbCellera/Eli Lilly and CompanyLatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Abcellera; Eli Lilly and Company
- Developer Abcellera; Eli Lilly and Company; National Institute of Allergy and Infectious Diseases
- Class Antibodies; Antivirals
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for research development in COVID-2019-infections in Canada (Parenteral)
- 28 Feb 2024 No recent reports of development identified for research development in COVID-2019-infections(Prevention) in Canada (Parenteral)
- 01 Jul 2020 Sanford Burnham Prebys Medical Discovery Institute enters into an research agreement with Eli Lilly and Company to characterise Lilly’s next-generation anti-SARS-CoV-2 antibodies